SECFilings.com, a renowned information and financial news portal releasing public company submission alerts, updated on the publication of an article throwing light on Supreme Pharmaceuticals, Inc. (OTCMKTS:SPRWF) and two other stocks in the related industry. The company belongs to the list of almost 40 licensed producers of medicinal pot under Health Canada’s ACMPR.
Supreme’s 7-acre hybrid greenhouse showcases the best practices of indoor grow with the cost setup of a greenhouse to yield high-quality pot at a low cost. Unlike several other licensed producers, the firm is focusing on the business-to-business industry where it will implement a wholesale business model. The firm expects that the greenhouse will be skilled of producing cannabis of more than 50 million grams annually at full capacity. Its next establishment will bring on an additional production space of 80,000 square feet in addition to the space of 40,000 square feet that’s already active.
Another firm that was talked about was AXIM Biotechnologies Inc., which is focused on expanding a portfolio of more than 20 cannabinoid-based nutraceuticals and pharmaceuticals along with 20 trademarks and 17 patents. The firm’s flagship products use its chewing gum-based delivery mechanism to provide clients with premium bioavailability without the negative side impacts or taking consuming edibles or stigma of smoking cannabis.
In recent months, the firm started early-stage clinical studies of its CanChew Plus for the cure of irritable bowel syndrome, as well as CanChew Rx for spasticity and pain in Multiple Sclerosis patients which is predicted to attain a market size of $20 billion by 2024. Moreover, the company finalized an association with a U.S. API firm to advance a substitute generic version of FDA-approved Marinol®. These clinical trials showcase multi-billion dollar industries where cannabinoids could demonstrate beneficial in providing people with much-needed relief.
In the last trading session, the stock price of Supreme declined more than 0.50% to close the day at $1.02.
2017 Most Disruptive Biotech VBIOhttp://www.financialstrend.com
Disruptive biotech VBIO decodes targeted drug delivery for stem cells
Enter The $100 Cannabis Markethttp://www.financialstrend.com
VBIO cannabis industry setup for explosive growth
Wall Street PR - BIG BUYOUT OPPORTUNITYhttp://wallstreetpr.com
Here’s how to leverage this breakthrough technology…
Can CBD Oil Get Rid of Chronic Pain?http://www.greenleaf.farm
Pure Colorado Golden CBD Oil Hemp Extracts
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure